184 related articles for article (PubMed ID: 15986399)
1. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
Pusztai L; Wagner P; Ibrahim N; Rivera E; Theriault R; Booser D; Symmans FW; Wong F; Blumenschein G; Fleming DR; Rouzier R; Boniface G; Hortobagyi GN
Cancer; 2005 Aug; 104(4):682-91. PubMed ID: 15986399
[TBL] [Abstract][Full Text] [Related]
2. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Sergieva SB; Timcheva KV; Hadjiolov ND
J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
[TBL] [Abstract][Full Text] [Related]
3. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
Fox E; Widemann BC; Pastakia D; Chen CC; Yang SX; Cole D; Balis FM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1273-83. PubMed ID: 26486517
[TBL] [Abstract][Full Text] [Related]
5. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.
Fox E; Bates SE
Expert Rev Anticancer Ther; 2007 Apr; 7(4):447-59. PubMed ID: 17428165
[TBL] [Abstract][Full Text] [Related]
6. Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer.
Kim R; Osaki A; Hirai T; Toge T
Breast Cancer; 2002; 9(3):240-7. PubMed ID: 12185336
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer.
Kawata K; Kanai M; Sasada T; Iwata S; Yamamoto N; Takabayashi A
Clin Cancer Res; 2004 Jun; 10(11):3788-93. PubMed ID: 15173086
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo reversal of chemoresistance by tariquidar (XR9576).
Di Nicolantonio F; Knight LA; Glaysher S; Whitehouse PA; Mercer SJ; Sharma S; Mills L; Prin A; Johnson P; Charlton PA; Norris D; Cree IA
Anticancer Drugs; 2004 Oct; 15(9):861-9. PubMed ID: 15457126
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.
Peck RA; Hewett J; Harding MW; Wang YM; Chaturvedi PR; Bhatnagar A; Ziessman H; Atkins F; Hawkins MJ
J Clin Oncol; 2001 Jun; 19(12):3130-41. PubMed ID: 11408511
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between uptake of 99Tcm-MIBI and expression of multidrug resistant protein in breast cancer].
Zhang XM; Zhang ZW; Wu H
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):353-5. PubMed ID: 15312346
[TBL] [Abstract][Full Text] [Related]
12. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Kostakoglu L; Elahi N; Kïratlï P; Ruacan S; Sayek I; Baltalï E; Sungur A; Hayran M; Bekdik CF
J Nucl Med; 1997 Jul; 38(7):1003-8. PubMed ID: 9225779
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
Abraham J; Edgerly M; Wilson R; Chen C; Rutt A; Bakke S; Robey R; Dwyer A; Goldspiel B; Balis F; Van Tellingen O; Bates SE; Fojo T
Clin Cancer Res; 2009 May; 15(10):3574-82. PubMed ID: 19417029
[TBL] [Abstract][Full Text] [Related]
15. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Kelly RJ; Draper D; Chen CC; Robey RW; Figg WD; Piekarz RL; Chen X; Gardner ER; Balis FM; Venkatesan AM; Steinberg SM; Fojo T; Bates SE
Clin Cancer Res; 2011 Feb; 17(3):569-80. PubMed ID: 21081657
[TBL] [Abstract][Full Text] [Related]
16. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
Ciarmiello A; Del Vecchio S; Silvestro P; Potena MI; Carriero MV; Thomas R; Botti G; D'Aiuto G; Salvatore M
J Clin Oncol; 1998 May; 16(5):1677-83. PubMed ID: 9586878
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
19. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography.
Mezi S; Primi F; Capoccetti F; Scopinaro F; Modesti M; Schillaci O
Int J Oncol; 2003 Jun; 22(6):1233-40. PubMed ID: 12738988
[TBL] [Abstract][Full Text] [Related]
20. Tc-99m MIBI liver imaging for hepatocellular carcinoma: correlation with P-glycoprotein-multidrug-resistance gene expression.
Chang CS; Yang SS; Yeh HZ; Kao CH; Chen GH
Hepatogastroenterology; 2004; 51(55):211-4. PubMed ID: 15011866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
